Assessing “Cell Therapy” Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States

Rajinder S. Nirwan, Thomas A Albini, Jayanth Sridhar, Harry W Flynn, Ajay E. Kuriyan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: “Cell therapy” is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of “cell therapy” clinics across the U.S. that advertise and offer “cell therapy” for ocular conditions based on information provided on their websites. Design: Cross-sectional study. Participants: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing “cell therapy” for ocular conditions as of September 16, 2017. Main Outcome Measures: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results: Forty companies with 76 clinics use “cell therapy” to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow–derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood–derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow–derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and “unspecified” (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised “cell therapy” ranged from $4000 to $10 500. Conclusions: “Cell therapy” for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The “cells” are harvested from numerous sources and administered through different methods for multiple ocular conditions at these “cell therapy” clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial “cell therapy” clinics.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Injections
Therapeutics
Ophthalmic Administration
Intraocular Injections
Direct-to-Consumer Advertising
Bone and Bones
Optic Neuritis
Intravitreal Injections
Ophthalmic Solutions
Vitrectomy
Macular Degeneration
Diabetic Retinopathy
Marketing
Fetal Blood
Intravenous Administration
Health Care Costs
Internet
Blood Cells

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Assessing “Cell Therapy” Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States. / Nirwan, Rajinder S.; Albini, Thomas A; Sridhar, Jayanth; Flynn, Harry W; Kuriyan, Ajay E.

In: Ophthalmology, 01.01.2019.

Research output: Contribution to journalArticle

@article{a64f9b0919584b50befc53eaa24849f3,
title = "Assessing “Cell Therapy” Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States",
abstract = "Purpose: “Cell therapy” is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of “cell therapy” clinics across the U.S. that advertise and offer “cell therapy” for ocular conditions based on information provided on their websites. Design: Cross-sectional study. Participants: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing “cell therapy” for ocular conditions as of September 16, 2017. Main Outcome Measures: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results: Forty companies with 76 clinics use “cell therapy” to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67{\%}), autologous bone marrow–derived stem cells (8; 15{\%}), amniotic stem cells (2; 4{\%}), peripheral blood–derived stem cells (2; 4{\%}), umbilical cord blood stem cells (2; 4{\%}), allogenic bone marrow–derived stem cells (1; 2{\%}), placental stem cells (1; 2{\%}), and xenocells (1; 2{\%}). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and “unspecified” (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised “cell therapy” ranged from $4000 to $10 500. Conclusions: “Cell therapy” for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The “cells” are harvested from numerous sources and administered through different methods for multiple ocular conditions at these “cell therapy” clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial “cell therapy” clinics.",
author = "Nirwan, {Rajinder S.} and Albini, {Thomas A} and Jayanth Sridhar and Flynn, {Harry W} and Kuriyan, {Ajay E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2019.03.019",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Assessing “Cell Therapy” Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States

AU - Nirwan, Rajinder S.

AU - Albini, Thomas A

AU - Sridhar, Jayanth

AU - Flynn, Harry W

AU - Kuriyan, Ajay E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: “Cell therapy” is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of “cell therapy” clinics across the U.S. that advertise and offer “cell therapy” for ocular conditions based on information provided on their websites. Design: Cross-sectional study. Participants: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing “cell therapy” for ocular conditions as of September 16, 2017. Main Outcome Measures: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results: Forty companies with 76 clinics use “cell therapy” to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow–derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood–derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow–derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and “unspecified” (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised “cell therapy” ranged from $4000 to $10 500. Conclusions: “Cell therapy” for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The “cells” are harvested from numerous sources and administered through different methods for multiple ocular conditions at these “cell therapy” clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial “cell therapy” clinics.

AB - Purpose: “Cell therapy” is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of “cell therapy” clinics across the U.S. that advertise and offer “cell therapy” for ocular conditions based on information provided on their websites. Design: Cross-sectional study. Participants: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing “cell therapy” for ocular conditions as of September 16, 2017. Main Outcome Measures: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results: Forty companies with 76 clinics use “cell therapy” to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow–derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood–derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow–derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and “unspecified” (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised “cell therapy” ranged from $4000 to $10 500. Conclusions: “Cell therapy” for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The “cells” are harvested from numerous sources and administered through different methods for multiple ocular conditions at these “cell therapy” clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial “cell therapy” clinics.

UR - http://www.scopus.com/inward/record.url?scp=85064325793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064325793&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2019.03.019

DO - 10.1016/j.ophtha.2019.03.019

M3 - Article

C2 - 30904542

AN - SCOPUS:85064325793

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -